BETA-2 score is an early predictor of graft decline and loss of insulin independence after pancreatic islet allotransplantation.
clinical research/practice
diabetes: type 1
islet transplantation
islets of Langerhans
quality of care/care delivery
Journal
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
ISSN: 1600-6143
Titre abrégé: Am J Transplant
Pays: United States
ID NLM: 100968638
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
20
06
2019
revised:
10
09
2019
accepted:
29
09
2019
pubmed:
10
10
2019
medline:
22
6
2021
entrez:
10
10
2019
Statut:
ppublish
Résumé
This study aimed to evaluate whether the BETA-2 score is a reliable early predictor of graft decline and loss of insulin independence after islet allotransplantation. Islet transplant procedures were stratified into 3 groups according to clinical outcome: long-term insulin independence without islet graft decline (group 1, N = 9), initial insulin independence with subsequent islet graft decline and loss of insulin independence (group 2, N = 13), and no insulin independence (group 3, N = 13). BETA-2 was calculated on day 75 and multiple times afterwards for up to 145 months posttransplantation. A BETA-2 score cut-off of 17.4 on day 75 posttransplantation was discerned between group 1 and groups 2 and 3 (area under the receiver operating characteristic 0.769, P = .005) with a sensitivity and negative predictive value of 100%. Additionally, BETA-2 ≥ 17.4 at any timepoint during follow-up reflected islet function required for long-term insulin independence. While BETA-2 did not decline below 17.4 for each of the 9 cases from group 1, the score decreased below 17.4 for all transplants from group 2 with subsequent loss of insulin independence. The reduction of BETA-2 below 17.4 predicted 9 (1.5-21) months in advance subsequent islet graft decline and loss of insulin independence (P = .03). This finding has important implications for posttransplant monitoring and patient care.
Identifiants
pubmed: 31597009
doi: 10.1111/ajt.15645
pii: S1600-6135(22)22248-5
doi:
Substances chimiques
Blood Glucose
0
C-Peptide
0
Insulin
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
844-851Subventions
Organisme : University of Chicago Diabetes Research and Training Center
Pays : International
Organisme : NIDDK NIH HHS
ID : P30 DK020595
Pays : United States
Organisme : Illinois Department of Public Health
Pays : International
Organisme : Dompe Pharmaceutical (Milan, Italy)
Pays : International
Informations de copyright
© 2019 The American Society of Transplantation and the American Society of Transplant Surgeons.
Références
Eich T, Eriksson O, Lundgren T. Visualization of early engraftment in clinical islet transplantation by positron-emission tomography. N Engl J Med. 2007;356(26):2754-2755.
McCall M, Shapiro AM. Update on islet transplantation. Cold Spring Harb Perspect Med. 2012;2(7):a007823.
Rickels MR, Robertson RP. Pancreatic islet transplantation in humans: recent progress and future directions. Endocr Rev. 2019;40(2):631-668.
Rickels MR, Liu C, Shlansky-Goldberg RD, et al. Improvement in β-cell secretory capacity after human islet transplantation according to the CIT07 protocol. Diabetes. 2013;62(8):2890-2897.
Dy EC, Harlan DM, Rother KI. Assessment of islet function following islet and pancreas transplantation. Curr Diab Rep. 2006;6(4):316-322.
Forbes S, Oram RA, Smith A, et al. Validation of the BETA-2 score: an improved tool to estimate beta cell function after clinical islet transplantation using a single fasting blood sample. Am J Transplant. 2016;16:2704-2713.
Ryan EA, Paty BW, Senior PA, et al. Beta-score: an assessment of beta-cell function after islet transplantation. Diabetes Care. 2005;28:343-347.
Tekin Z, Garfinkel MR, Chon WJ, et al. Outcomes of pancreatic allotransplantation using the Edmonton protocol at the University of Chicago. Transplant Direct. 2016;13:2.
Vantyghem M-C, Raverdy V, Balavoine A-S, et al. Continuous glucose monitoring after islet transplantation in type 1 diabetes: an excellent graft function (β-score greater than 7) is required to abrogate hyperglycemia, whereas a minimal function is necessary to suppress severe hypoglycemia (β-score greater than 3). J Clin Endocrinol Metab. 2012;97:E2078-E2083.
Bellin MD, Kandaswamy R, Parkey J, et al. Prolonged insulin independence after allotransplants in recipients with type 1 diabetes. Am J Transplant. 2008;8:2463-2470.
Rickels MR, Stock PG, de Koning E, et al. Defining outcomes for β-cell replacement therapy in the treatment of diabetes: a consensus report on the Igls criteria from the IPITA/EPITA opinion leaders workshop. Transplantation. 2018;102(9):1479-1486.
Ohkura T, Shiochi H, Fujioka Y, et al. 20/(fasting C-peptide × fasting plasma glucose) is a simple and effective index of insulin resistance in patients with type 2 diabetes mellitus: a preliminary report. Cardiovasc Diabetol. 2013;22:12-21.
Herold KC, Usmani-Brown S, Ghazi T, et al. β cell death and dysfunction during type 1 diabetes development in at-risk individuals. J Clin Invest. 2015;125:1163-1173.
Gołębiewska J, Solomina J, Kijek MR, et al. External validation of the newly developed BETA-2 scoring system for pancreatic islet graft function assessment. Transplant Proc. 2017;49:2340-2346.
Gołębiewska JE, Solomina J, Thomas C, et al. Comparative evaluation of simple indices using a single fasting blood sample to estimate beta cell function after islet transplantation. Am J Transplant. 2018;18:990-997.